4DMT acquires all world-wide rights to short-form human complement factor H (sCFH) from Aevitas Therapeutics, Inc.; technology invented at University of Pennsylvania Announces sCFH as payload for ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Many novel treatment approaches are being investigated to halt progression of geographic atrophy (GA) or, potentially, even reverse the retinal damage. The major categories include novel complement ...

Ophthalmologists are cautious about prescribing the current geographic atrophy (GA) treatment options Syfovre and Izervay, introduced in 2023 as the first-ever therapy for GA, according to Spherix ...

Expert panelists evaluate results regarding complement inhibitor trials for utilization in PNH management. Several complement inhibitors have been approved since eculizumab, including ravulizumab, a ...